Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

A. Samer Al-Homsi, MD, Austin Goodyke, Kelli Cole, MSN, Marlee Muilenburg, BSN, Michael McLane, Sarah Abdel-Mageed, Muneer H. Abidi, MD, Stephanie F. Williams, MD

Blood (2016) 128 (22): 4543.

https://doi.org/10.1182/blood.V128.22.4543.4543

Published: 2016

Journal Articles

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

A. Samer Al-Homsi, MD, Marlee Muilenburg, BSN, Kelli Cole, MSN, Muneer H. Abidi, MD, Stephanie F. Williams, MD

Blood (2016) 128 (22): 4635.

https://doi.org/10.1182/blood.V128.22.4635.4635

Published: 2016

Journal Articles

Post-Transplant Cyclophosphamide and Bortezomib Combination for Prevention of GvHD after Allogeneic Blood and Marrow Transplantation Is Feasible and Produces Favorable Outcomes

A. Samer Al-Homsi, MD, Tara S Roy, NP, Kelli Cole, RN, MSN, Marlee Bogema, RN, BSN, Stephanie F Williams, MD, Ulrich A. Duffner, MD, Aly Mageed, MD

Blood (2014) 124 (21): 3920.

https://doi.org/10.1182/blood.V124.21.3920.3920

Published: 2014

Journal Articles

Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin’s Lymphoma

Neelima Vidula, MD, Borko Jovanovic, PhD, Jane N. Winter, MD, Jayesh Mehta, MD, Seema Singhal, MD, Stephanie F. Williams, MD, Olga Frankfurt, MD, Jessica K. Altman, MD, Joanne Monreal, AAS, Andrew M. Evens, DO, MSc, Leo I. Gordon, MD, FACP

Blood (2011) 118 (21): 4499.

https://doi.org/10.1182/blood.V118.21.4499.4499

Published: 2011

Journal Articles

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

Paul Richardson, Sundar Jagannath, Mohamad Hussein, James Berenson, Seema Singhal, David Irwin, Stephanie F. Williams, William Bensinger, Ashraf Z. Badros, Robert Vescio, Laurie Kenvin, Zhinuan Yu, Marta Olesnyckyj, Jerome Zeldis, Robert Knight, Kenneth C. Anderson

Blood (2009) 114 (4): 772–778.

https://doi.org/10.1182/blood-2008-12-196238

Published: 2009

Journal Articles

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Paul Richardson, MD, Sundar Jagannath, MD, Mohamad Hussein, MD, James Berenson, MD, Seema Singhal, MD, David Irwin, MD, Stephanie F. Williams, MD, William Bensinger, MD, Ashraf Z. Badros, MD, Robert Vescio, MD, Laurie Kenvin, BSN, Zhinuan Yu, PhD, Marta Olesnyckyj, RN, BSN, Herbert Faleck, DO, Jerome Zeldis, MD, Robert Knight, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 1565.

https://doi.org/10.1182/blood.V106.11.1565.1565

Published: 2005

Journal Articles

Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkin’s Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.

Jessica K. Altman, MD, Leo I. Gordon, MD, Joanne Monreal, Andrew M. Evens, DO, Stephanie F. Williams, MD, Martin S. Tallman, MD, Seema Singhal, MD, Jayesh Mehta, MD, Jane N. Winter, MD

Blood (2005) 106 (11): 5455.

https://doi.org/10.1182/blood.V106.11.5455.5455

Published: 2005

Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.

Jane N. Winter, M.D., David J. Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie F. Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.

Blood (2004) 104 (11): 1162.

https://doi.org/10.1182/blood.V104.11.1162.1162

Published: 2004

Journal Articles

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study

Catherine Metayer, Rochelle E. Curtis, Julie Vose, Kathleen A. Sobocinski, Mary M. Horowitz, Smita Bhatia, Joseph W. Fay, Cesar O. Freytes, Steven C. Goldstein, Roger H. Herzig, Armand Keating, Carol B. Miller, Thomas J. Nevill, Andrew L. Pecora, J. Douglas Rizzo, Stephanie F. Williams, Chin-Yang Li, Lois B. Travis, Daniel J. Weisdorf

Blood (2003) 101 (5): 2015–2023.

https://doi.org/10.1182/blood-2002-04-1261

Published: 2003

Journal Articles

A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients

Elizabeth J. Shpall, Catherine A. Wheeler, Stewart A. Turner, Saul Yanovich, Randy A. Brown, Andrew L. Pecora, Thomas C. Shea, Kenneth F. Mangan, Stephanie F. Williams, C. Fred LeMaistre, Gwynn D. Long, Roy Jones, Mark W. Davis, Robyn Murphy-Filkins, William R.L. Parker, John A. Glaspy

Blood (1999) 93 (8): 2491–2501.

https://doi.org/10.1182/blood.V93.8.2491

Published: 1999

NARROW

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

Post-Transplant Cyclophosphamide and Bortezomib Combination for Prevention of GvHD after Allogeneic Blood and Marrow Transplantation Is Feasible and Produces Favorable Outcomes

Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin’s Lymphoma

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results.

Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkin’s Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.

90 Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study

A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only